Search Results - "Aitken, Marisa J L"

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia by Aitken, Marisa J. L, Ravandi, Farhad, Patel, Keyur P, Short, Nicholas J

“…Abstract Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms…”
Get full text

Emerging treatment options for patients with p53-pathway-deficient CLL by Aitken, Marisa J. L., Lee, Hun J., Post, Sean M.

“…Over the past 40 years, p53 has been the most widely studied protein in cancer biology. Originally thought to be an oncogene due to its stabilization in many…”
Get full text

Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas by Gallardo, Miguel, Malaney, Prerna, Aitken, Marisa J L, Zhang, Xiaorui, Link, Todd M, Shah, Vrutant, Alybayev, Sanzhar, Wu, Meng-Han, Pageon, Laura R, Ma, Huaxian, Jacamo, Rodrigo, Yu, Li, Xu-Monette, Zijun Y, Steinman, Haley, Lee, Hun Ju, Sarbassov, Dos, Rapado, Inmaculada, Barton, Michelle C, Martinez-Lopez, Joaquin, Bueso-Ramos, Carlos, Young, Ken H, Post, Sean M

“…Abstract Background Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is an RNA-binding protein that is aberrantly expressed in cancers. We and others have…”
Get full text

The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies by Malaney, Prerna, Velasco-Estevez, María, Aguilar-Garrido, Pedro, Aitken, Marisa J L, Chan, Lauren E, Zhang, Xiaorui, Post, Sean M, Gallardo, Miguel

“…B-cell lymphomas are one of the most biologically and molecularly heterogeneous group of malignancies. The inherent complexity of this cancer subtype…”
Get full text

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML by Herbrich, Shelley, Baran, Natalia, Cai, Tianyu, Weng, Connie, Aitken, Marisa J L, Post, Sean M, Henderson, Jared, Shi, Chunhua, Havranek, Ondrej, Richard-Carpentier, Guillame, Sauvageau, Guy, Baggerly, Keith, Al-Atrash, Gheath, Davis, R Eric, Daver, Naval, Zha, Dongxing, Konopleva, Marina

“…BackgroundAcute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed…”
Get full text

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy by Kannan, Sankaranarayan, Irwin, Mary E, Herbrich, Shelley M, Cheng, Tiewei, Patterson, LaNisha L, Aitken, Marisa J L, Bhalla, Kapil, You, M James, Konopleva, Marina, Zweidler-McKay, Patrick A, Chandra, Joya

“…Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication…”
Get full text

Thirty‐three years later: Two distinct cases of acute lymphoblastic leukemia in one patient by Aitken, Marisa J.L., Benton, Christopher B., Wang, Feng, Zhang, Jianhua, Herbrich, Shelley M., Takahashi, Koichi, Bueso‐Ramos, Carlos E., Short, Nicholas J.

Get full text

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3 -ITD acute myeloid leukemia by Post, Sean M, Ma, Huaxian, Malaney, Prerna, Zhang, Xiaorui, Aitken, Marisa J L, Mak, Po Yee, Ruvolo, Vivian R, Yasuhiro, Tomoko, Kozaki, Ryohei, Chan, Lauren E, Ostermann, Lauren B, Konopleva, Marina, Carter, Bing Z, DiNardo, Courtney, Andreeff, Michael D, Khoury, Joseph D, Ruvolo, Peter P

“…FMS-like Tyrosine Kinase 3 (FLT3) mutation is associated with poor survival in acute myeloid leukemia (AML). The specific Anexelekto/MER Tyrosine Kinase (AXL)…”
Get full text

Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer by Aitken, Marisa J L, Benton, Christopher B, Issa, Ghayas C, Sasaki, Koji, Yilmaz, Musa, Short, Nicholas J

“…CML is defined by the presence of an oncogenic fusion protein caused by a reciprocal translocation between chromosomes 9q and 22q. While our molecular…”
Get more information

Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia by Kannan, Sankaranarayanan, Aitken, Marisa J L, Herbrich, Shelley M, Golfman, Leonard S, Hall, Mandy G, Mak, Duncan H, Burks, Jared K, Song, Guangchun, Konopleva, Marina, Mullighan, Charles G, Chandra, Joya, Zweidler-McKay, Patrick A

“…In B-cell acute lymphoblastic leukemia (B-ALL), activation of Notch signaling leads to cell-cycle arrest and apoptosis. We aimed to harness knowledge acquired…”
Get full text

Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing by Aitken, Marisa J L, Malaney, Prerna, Zhang, Xiaorui, Herbrich, Shelley M, Chan, Lauren, Benitez, Oscar, Rodriguez, Ashley G, Ma, Huaxian, Jacamo, Rodrigo, Duan, Ruizhi, Link, Todd M, Kornblau, Steven M, Kanagal-Shamanna, Rashmi, Bueso-Ramos, Carlos E, Post, Sean M

“…Acute myeloid leukemia (AML) is driven by numerous molecular events that contribute to disease progression. Herein, we identify hnRNP K overexpression as a…”
Get full text

Anti-Leukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia by Kannan, Sankaranarayanan, Aitken, Marisa J. L., Herbrich, Shelley M., Golfman, Leonard S., Hall, Mandy G., Mak, Duncan H, Burks, Jared K, Song, Guangchun, Konopleva, Marina, Mullighan, Charles G., Chandra, Joya, Zweidler-McKay, Patrick A.

“…In B cell acute lymphoblastic leukemia (B-ALL), activation of Notch signaling leads to cell-cycle arrest and apoptosis. We aimed to harness knowledge acquired…”
Get full text